{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:00:18Z","timestamp":1790290818098,"version":"4.1.0"},"reference-count":11,"publisher":"Georg Thieme Verlag KG","issue":"03","license":[{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Nucl Med"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Radioactive iodine refractory (RAIR) thyroid cancer and thyroglobulin elevated negative iodine scintigraphy constitute a fraction of thyroid cancer patients with poorer prognosis as opposed to radioiodine concentrating disease. Although not a rare condition and with several treatment options already explored, the selection of an optimal therapy that balances effective disease stabilization, symptom palliation, life prolongation, and minimal side effects remains essential. The use of multi-tracer positron emission tomography (PET) shows potential for radionuclide therapy selection in RAIR thyroid cancer. In this case report, multi-tracer PET imaging was employed to assess the feasibility of available theranostic options. While [68Ga]Ga-DOTATATE PET\/computed tomography (CT) showed low-level somatostatin receptor expression, [68Ga]Ga-prostate specific membrane antigen (PSMA)-11 PET\/CT revealed moderate and concordant PSMA expression across all lesions observed on [18F]F-FDG PET\/CT, justifying [177Lu]Lu-PSMA-617 therapy in this patient.<\/jats:p>","DOI":"10.1055\/s-0045-1812056","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T22:30:17Z","timestamp":1759617017000},"page":"266-270","source":"Crossref","is-referenced-by-count":0,"title":["Multi-Tracer PET-Guided Therapy Selection and Theranostics in Radioiodine-Refractory Thyroid Cancer Patient Unsuitable for Tyrosine Kinase Inhibitor Therapy"],"prefix":"10.1055","volume":"25","author":[{"given":"Austin","family":"Saju","sequence":"additional","affiliation":[{"name":"Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Jerbai Wadia Road, Parel, Mumbai, Maharashtra, India"},{"name":"Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8751-0481","authenticated-orcid":false,"given":"Sunita","family":"Sonavane","sequence":"additional","affiliation":[{"name":"Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Jerbai Wadia Road, Parel, Mumbai, Maharashtra, India"},{"name":"Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6607-2558","authenticated-orcid":false,"given":"Sandip","family":"Basu","sequence":"additional","affiliation":[{"name":"Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Jerbai Wadia Road, Parel, Mumbai, Maharashtra, India"},{"name":"Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,10,4]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"B R Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13550-020-0610-x","article-title":"68Ga-PSMA PET\/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617","volume":"10","author":"L H de Vries","year":"2020","journal-title":"EJNMMI Res"},{"issue":"08","key":"ref3","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"C Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"07","key":"ref4","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"M Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial","volume":"384","author":"M S Brose","year":"2014","journal-title":"Lancet"},{"issue":"02","key":"ref6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-DOTATATE for midgut neuroendocrine tumors","volume":"376","author":"J Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"O Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"06","key":"ref8","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"M S Hofman","year":"2018","journal-title":"Lancet Oncol"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1038\/s41598-017-05481-z","article-title":"PSMA expression by microvasculature of thyroid tumors - potential implications for PSMA theranostics","volume":"7","author":"A Bychkov","year":"2017","journal-title":"Sci Rep"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4103\/wjnm.WJNM_112_18","article-title":"177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment","volume":"18","author":"M Assadi","year":"2019","journal-title":"World J Nucl Med"},{"issue":"08","key":"ref11","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1097\/RLU.0000000000003655","article-title":"Prostate-specific membrane antigen expression in patients with differentiated thyroid cancer with thyroglobulin elevation and negative iodine scintigraphy using 68Ga-PSMA-HBED-CC PET\/CT","volume":"46","author":"P Verma","year":"2021","journal-title":"Clin Nucl Med"}],"container-title":["World Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0045-1812056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:31:02Z","timestamp":1790289062000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0045-1812056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,4]]},"references-count":11,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2026,9,24]]},"published-print":{"date-parts":[[2026,9]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0045-1812056","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1450-1147","1607-3312"],"issn-type":[{"value":"1450-1147","type":"print"},{"value":"1607-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,4]]}}}